GlassScriptPhysician profile
Thomas S Dawson
NPI 1366450744
$1,439.20
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,439.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $311.69 | 2019 | |
| Janssen Pharmaceuticals, INC | $258.67 | 2019 | |
| Pfizer INC. | $177.55 | 2019 | |
| Amgen INC. | $160.09 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $67.04 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $65.03 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $53.22 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.85 | 2019 | |
| Abbott Laboratories | $34.54 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $32.10 | 2019 | |
| Shire North American Group INC | $24.97 | 2019 | |
| Novo Nordisk INC | $23.78 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $21.18 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.71 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $18.27 | 2019 | |
| Lilly USA, LLC | $18.12 | 2019 | |
| Antares Pharma, INC. | $15.46 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.67 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Dawson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.